Dr. Reddy's API plant still struggling to satisfy FDA

Dr. Reddy's tablets
Dr. Reddy's Laboratories has received another Form 483 for a plant that makes APIs used to manufacture finished products. (Dr. Reddy's)

Dr. Reddy’s has spent nearly five years trying to get out from under a warning letter for an important API plant in India but has yet to shake off all of the FDA’s concerns. In fact, a new FDA filing raises issues about out-of-spec drugs and cleaning of solvents off equipment at the plant.  

The highly redacted, five-observation Form 483 is for Dr. Reddy’s Unit VI API plant in Srikakulam District, Andhra Pradesh, one of three plants cited in a 2015 warning letter. Among other issues, the January inspection was critical of the plant’s investigations of out-of-specification tests. It also said the plant did not even test “for unknown peaks in residual solvents,” in one batch of drugs.

RELATED: Dr. Reddy's blasted in warning letter for hiding existence of testing lab from FDA

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

The inspectors' observations about the plant's equipment cleaning focused in part on production of an API that the citation does not publicly name. It said an unsatisfactory cleaning validation might be associated with OSS peaks in it and "unknown peaks in other manufactured APIs … which are pending applications in the United States.” It also faulted the company for not conducting a trend analysis on those peaks. 

RELATED: What has Zantac recall cost drugmakers? Dr. Reddy's gives a hint

The inspection report does not name any specific drugs but the discussion of solvents, mentioned six times, underscores the FDA’s focus on them after finding that solvents play a key part in the creation of suspected carcinogens in sartans and ranitidine drugs. 

Dr. Reddy’s is among drugmakers that voluntarily recalled ranitidine, generic Zantac, from the market last year after the FDA determined that unacceptable levels of N-nitrosodimethylamine were being created through manufacturing. The company reported the recall of 33 different ranitidine products last fall cost it about $25 million in that quarter. 


Suggested Articles

The U.K. became the first Western country to authorize a COVID vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.